BBIO Stock Surges 16% As AstraZeneca-Ionis Heart Drug Trial Misses Goal — BofA Calls Failure ‘A Big Surprise’
AstraZeneca and Ionis announced on Thursday that their late-stage CARDIO-TTRansform trial for eplontersen (Wainua) failed to meet its main goal.
Read the full articleYou might also wanna read
AstraZeneca’s Wainua fails main goal in late-stage heart disease trial
Drug developed with Ionis could not reduce cardiovascular deaths or recurring heart problems
AstraZeneca sees stock market value slump by more than £20bn after drug setback
The FTSE 100 firm found the Wainua drug failed to meet a goal to reduce deaths related to heart disease.
AstraZeneca sees stock market value slump by more than £20bn after drug setback
The FTSE 100 firm found the Wainua drug failed to meet a goal to reduce deaths related to heart disease.
Astrazeneca shares fall 9% after Wainua heart drug fails Phase 3 trial
Svensk-britiske Astrazeneca er havnet i modvind på børsen torsdag oven på et sæt skuffende resultater fra et fase 3-studie med hjertemidlet
finans.dk·21h agoDividenden-Garant Astrazeneca im freien Fall: Studien-Flop schockt Anleger
Nackenschlag für den britisch-schwedischen Pharma-Konzern Astrazeneca und den Entwicklungspartner Ionis Pharmaceuticals. Der Hoffnungsträger
STAT+: AstraZeneca, Ionis report major trial failure with heart disease drug
AstraZeneca and Ionis reported a notable trial failure Thursday in a heart disease that's become an increasingly competitive market for drug
Comments
Sign in to join the conversation.
No comments yet. Be the first.